Zhongwei Sun

Zhongwei Sun is a professional with over 10 years of experience in Cell Therapy, specializing in Phase I and II MRCT-clinical trials and IND applications to cFDA/NMPA and FDA.

His expertise includes working with Cell and Gene therapy products such as Stem cell, CAR-T cell, and Apheresis systems.

In addition, he has a strong background in Global Supply chain management and depot management of Cell Therapy Products.

Zhongwei Sun's professional interests lie in Cell therapy, Hematology, and Oncology, with prior affiliations with Terumo Medical Corporation and Cellular Biomedicine Group (NASDAQ: CBMG).

He holds a Doctor of Philosophy (Ph.D.) in Stem Cell Biology from MPI-CBG-Max Planck Institute of Molecular Cell Biology and Genetics, a master's degree in Biochemistry and Molecular Biology from East China Normal University, and another Ph.D. in Regenerative Therapy-Stem Cell Biology from Technische Universität Dresden.

Currently, Zhongwei Sun serves as a Project Director at Fosun Pharma.